Besifloxacin: A Critical Review of Its Characteristics, Properties, and Analytical Methods
- PMID: 29345957
- DOI: 10.1080/10408347.2018.1429885
Besifloxacin: A Critical Review of Its Characteristics, Properties, and Analytical Methods
Abstract
Bacterial conjunctivitis has high impact on the health of the population, since it represents more than a third of ocular pathologies reported by health services worldwide. There is a high incidence of bacterial resistance to the antimicrobials most commonly used for the treatment of conjunctivitis. In this context, besifloxacin stands out, since it is a fluoroquinolone developed exclusively for topical ophthalmic use, presenting a low risk of developing resistance due to its reduced systemic exposure. Bausch & Lomb markets it as ophthalmic suspension, under the trade name Besivance™. Literature review on besifloxacin is presented, covering its pharmaceutical and clinical characteristics, and the analytical methods used to measure the drug in pharmaceutical products and biological samples. High performance liquid chromatography is the most used method for this purpose. A discussion on Green Chemistry is also presented, focusing the importance of the development of green analytical methods for the analysis of drugs.
Keywords: Analytical methods; besifloxacin; fluoroquinolones; green analytical chemistry; quality control.
Similar articles
-
Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.Clin Ther. 2010 Mar;32(3):454-71. doi: 10.1016/j.clinthera.2010.03.013. Clin Ther. 2010. PMID: 20399984 Review.
-
Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.J Antimicrob Chemother. 2010 Jul;65(7):1441-7. doi: 10.1093/jac/dkq127. Epub 2010 Apr 30. J Antimicrob Chemother. 2010. PMID: 20435780 Free PMC article.
-
Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis.Adv Ther. 2012 Jun;29(6):473-90. doi: 10.1007/s12325-012-0027-7. Epub 2012 Jun 20. Adv Ther. 2012. PMID: 22729919 Review.
-
Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.J Ocul Pharmacol Ther. 2010 Oct;26(5):449-58. doi: 10.1089/jop.2010.0054. J Ocul Pharmacol Ther. 2010. PMID: 20874668
-
Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.Clin Ther. 2009 Mar;31(3):514-26. doi: 10.1016/j.clinthera.2009.03.010. Clin Ther. 2009. PMID: 19393842 Clinical Trial.
Cited by
-
Potential new fluoroquinolone treatments for suspected bacterial keratitis.BMJ Open Ophthalmol. 2022 Jul;7(1):e001002. doi: 10.1136/bmjophth-2022-001002. BMJ Open Ophthalmol. 2022. PMID: 36161851 Free PMC article. Review.
-
HPLC methods for choloroquine determination in biological samples and pharmaceutical products.Daru. 2021 Jun;29(1):223-239. doi: 10.1007/s40199-021-00391-y. Epub 2021 Mar 19. Daru. 2021. PMID: 33738722 Free PMC article. Review.
-
Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones-Shaping the Fifth Generation.Pharmaceutics. 2021 Aug 18;13(8):1289. doi: 10.3390/pharmaceutics13081289. Pharmaceutics. 2021. PMID: 34452252 Free PMC article. Review.
-
Synthesis and Antibacterial Evaluation of Ciprofloxacin Congeners with Spirocyclic Amine Periphery.Int J Mol Sci. 2023 Jan 4;24(2):954. doi: 10.3390/ijms24020954. Int J Mol Sci. 2023. PMID: 36674469 Free PMC article.
-
Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?Pharmaceutics. 2023 Mar 1;15(3):804. doi: 10.3390/pharmaceutics15030804. Pharmaceutics. 2023. PMID: 36986665 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical